China’s edge in fast, cost-effective early clinical trials has propelled its emergence as a global biopharmaceutical powerhouse, but there is a risk that the United States could take steps to curb that advantage, according to analysts.
US lawmakers and officials at the Food and Drug Administration (FDA) have raised the alarm about American pharmaceutical companies’ growing reliance on conducting early clinical trials in China, flagging the opaqueness of the process and the need to keep medical...
Rising US scrutiny on clinical trials could threaten China’s biotech advantage: analysts
Global - Asia
Archived
•
September 22, 2026
•
2 views
Source: South China Morning Post | https://www.scmp.com/rss/91/feed - Read Original
Discussion (0)
Please log in to post a comment.
No comments yet. Be the first to share your thoughts!



